Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

Cancer

Volumn 115, Issue 8, 2009, Pages 1734-1743

  Chamberlain, Marc C ^a,b   Johnston, Sandra ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alkylator; Bevacizumab; Chemotherapy; Recurrent anaplastic oligodendroglioma; Refractory

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ANAPLASTIC OLIGODENDROGLIOMA; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEURORADIOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; THROMBOPHLEBITIS; TREATMENT RESPONSE; TUMOR GROWTH; WOUND DEHISCENCE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 65249083423     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24179     Document Type: Article

References (54)

1. The Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research Council Trial. J Clin Oncol. 2000;19:509-518.
2. Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999;17:3389-3395.
3. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable Carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.
4. Grossman SA, O'Neill A, Grunnet M, et al. Phase III study comparing 3 cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003;21:1485-1491.
5. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol. 2000;27(suppl 3):1-10.
6. Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant ''boost'' in the initial treatment of malignant gliomas: NCOG Study 6G82-2. Int J Radiat Oncol Biol Phys. 1991;21:601.
7. Kornblith PD, Welch WC, Bradley MK. The future of therapy for glioblastoma. Surg Neurol. 1993;39:538-543.
8. Loeffler JS, Alexander E, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992;10:1379-1385.
9. Prados MD, Gutin PH, Phillips TL, et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys. 1992;24:593.
10. Levin VA, Silver P, Hannigan J, et al. Superiority of post- radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321-324.
11. Stewart LA. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet. 2002;359:1011-1018.
12. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy and without chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-2597.
13. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
14. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant gliomas: a phase II study. J Clin Oncol 1991;9:860.
15. Allen JC, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987;5:759- 763.
16. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
17. See SJ, Levin VA, Yung A, et al. 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004;6:253-258.
18. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg. 1981;55:749-756.
19. Longee DC, Friedman HS, Albright RE, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg. 1990;72:583-588.
20. Chamberlain MC, TSão-Wei D. Recurrent glioblastoma multiforme: salvage therapy with cyclophosphamide. Cancer. 2004;100:1213-1220.
21. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant gli- oma. J Clin Oncol. 1990;8:1277-1280.
22. Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys. 1992;23:3-8.
23. Tortosa A, Vinolas N, Villa S, et al. Prognostic implications of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97:1063-1071.
24. Chamberlain M, Glantz MJ. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. Cancer. 2008;112:2038-2045.
25. Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trial Groups. J Clin Oncol. 2004;22:1s.
26. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008-1012.
27. Jaeckle KA, Hess KR, Yung A, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003;21:2305-2311.
28. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 2005;7:369.
29. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260.
30. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
31. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizu- mab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
32. Chen C, Silverman DHS, Geist C, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
33. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology. 2008;70:779-787.
34. Cloughesy T, Prados MD, Mikkelsen T, et al. A phase 2 randomized non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma [abstract]. J ClinOncol.2008;26: 91s.
35. Miller RG Jr. Survival Analysis. New York: John Wiley & Sons; 1981:114-118.
36. Pike MC. Contribution to the discussion on the paper by R. Peto and J. Peto, ''Asymptotically efficient rank invariant procedures.'' J R Stat Soc (Series A). 1972;135:201-203.
37. Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med. 1991;10:749-755.
38. Lawless JF. Statistical Models and Methods for Lifetime Data. New York: John Wiley & Sons; 1982:345-354.
39. Kaplan EL, Meier P. Nonparametric estimation form incomplete observations. J Am Stat Assoc. 1958;53:457-481.
40. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J Clin Oncol. 2006;24:2707-2714.
41. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocyto- mas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J Clin Oncol. 2006;24:2715-2722.
42. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004;6:21-27.
43. Buckner JC, Reid JM, Wright K, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Cancer Central Treatment Group. Cancer. 2003;97:2352-2358.
44. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56: 183-188.
45. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every 3-week regimen. Cancer. 2003;97:2381-2386.
46. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
47. Prados MD, Yung WKA, Jaeckle KA, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004;6:44-54.
48. Soffieti R, Nobile M, Rida F, et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV chemotherapy: a phase II study. Cancer. 2004;15:807-813.
49. Brandes AA, Basso U, Vastola F, et al. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol. 2003;14:1727-1731.
50. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95.
51. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. EurJ Cancer. 1997;33:1592-1596.
52. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89:640-646.
53. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;l06:601-608.
54. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9:89-95.